Abstract: The invention provides a method of purifying 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, comprising adding a portion of acid to a stream comprising crude 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide in a solvent and continuously crystallising the 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide from the crude 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, with removal of at least a fraction of the solvent, wherein the crystallisation is carried out in a continuous reactor, wherein the continuous reactor is a plug flow reactor. At least three further portions of acid are added to the continuous reactor during the crystallisation.

Abstract: Alternative continuous downstream processes for the production of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.

Abstract: Alternative continuous downstream processes for the production of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.

Abstract: Alternative continuous downstream processes for the production of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.

Abstract: Alternative continuous downstream processes for the production of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.

Abstract: Alternative continuous downstream processes for the production of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.

Abstract: Alternative continuous downstream processes for the production of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.

Abstract: This invention relates to the isolation of iodixanol (1,3-bis(acetamido)-N,N?-bis[3,5-bis(2,3-dihydroxypropylaminocarbonyl)-2,4,6-triiodophenyl]-2-hydroxypropane), more specifically to the isolation of iodixanol from an aqueous solution.

Abstract: This invention relates to an improved method for the synthesis of 5-amino-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (Compound B), an intermediate in the industrial preparation of non-ionic X-ray contrast agents. In particular, it relates to a continuous process of the iodination reaction followed by the purification of Compound B.

Abstract: This invention relates to an improved method for the synthesis of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”), an intermediate in the industrial preparation of non-ionic X-ray contrast agents. In particular, it relates to a continuous process of deacetylation of the acetylated hydroxyl group in 5-amino-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide (“Compound B”) followed by crystallisations, filtration, and washing of Compound A.